Cullinan Therapeutics, Inc. (CGEM) Revenue History
Annual and quarterly revenue from 2018 to present
CGEM Revenue Over Time (2018–2025)
CGEM Revenue Growth History
0 of 1 years with positive growth- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -100.0%
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
CGEM Revenue Analysis (2018–2025)
Current Revenue & Growth
As of June 22, 2026, Cullinan Therapeutics, Inc. (CGEM) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
CGEM's historical revenue data shows various trends over time. Cullinan Therapeutics, Inc.'s highest annual revenue of $18.9 million was recorded in 2021.
Peer Comparison
Compared to Healthcare sector peers — including KYMR (-12.6% YoY), RCUS (+67.4% YoY), and PRCT (+29.3% YoY). Compare CGEM vs KYMR →
CGEM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CGEMCurrent | $0 | - | - | - | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 PRCT | $308M | +29.3% | +109.0% | -33.7% |
CGEM Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-241,648,000 | - |
| 2024 | $0 | - | $-306,000 | - | $-196,919,000 | - |
| 2023 | $0 | - | $0 | - | $-191,089,000 | - |
| 2022 | $0 | -100.0% | $0 | - | $144.6M | - |
| 2021 | $18.9M | - | $18.9M | 100.0% | $-67,954,000 | -358.7% |
| 2020 | $0 | - | $-62,000 | - | $-60,335,000 | - |
| 2019 | $0 | - | $-70,000 | - | $-22,270,000 | - |
| 2018 | $0 | - | $-43,000 | - | $-14,586,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CGEM — Frequently Asked Questions
Quick answers to the most common questions about buying CGEM stock.
Is CGEM's revenue growth accelerating or slowing?
CGEM TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is CGEM's revenue history from 2018 to 2026?
Cullinan Therapeutics, Inc. (CGEM) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CGEM's long-term revenue growth rate (CAGR)?
Cullinan Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CGEM.
Why does CGEM's quarterly revenue fluctuate?
CGEM quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Cullinan Therapeutics, Inc.'s revenue data from 2018 to 2026 shows full historical quarterly detail on this page.
How is CGEM's revenue distributed by segment?
CGEM reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CGEM's revenue compare to industry peers?
Cullinan Therapeutics, Inc. (CGEM) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.